ExPEC10V
Pharmaceutical compound
From Wikipedia, the free encyclopedia
ExPEC10V, also known as VAC-52416 or JNJ-69968054, is a vaccine against Escherichia coli infection.[1][2] It is an Escherichia coli polysaccharide conjugate vaccine.[1][2] The vaccine is administered by intramuscular injection.[1] It is being developed by Janssen Pharmaceuticals.[1] As of April 2023, ExPEC10V is in phase 3 clinical trials.[1] It is under development towards approval in the United States, Europe, and Japan.[1] The vaccine is a 10-valent form of the earlier ExPEC4V.[2]
TargetEscherichia coli
Other namesExPEC10-V; ExPEC-10V; ExPECV10; ExPEC-V10; VAC-52416; VAC52416; JNJ-69968054; JNJ69968054
| Vaccine description | |
|---|---|
| Target | Escherichia coli |
| Vaccine type | Conjugate |
| Clinical data | |
| Other names | ExPEC10-V; ExPEC-10V; ExPECV10; ExPEC-V10; VAC-52416; VAC52416; JNJ-69968054; JNJ69968054 |
| Routes of administration | Intramuscular injection |
